Understanding Pre-eclampsia and Its Risks

Overview of Pre-eclampsia

Pre-eclampsia is a significant complication affecting 2-3% of pregnancies. This condition poses heightened risks for both maternal and fetal health, particularly if it leads to preterm delivery before 37 weeks of gestation. Recent studies indicate that preventive use of aspirin can lower the risk of developing preterm pre-eclampsia.

Impact of Aspirin in Prevention

A meta-analysis involving 18,907 participants found that prophylactic doses of aspirin greater than 100mg reduced the incidence of preterm pre-eclampsia by 67%. This highlights the importance of early intervention for at-risk individuals.

Research on Risk Assessment Methods

Study Overview

A recent multicenter study published in *Ultrasound in Obstetrics & Gynecology* investigated the effectiveness of the National Institute for Health and Care Excellence (NICE) guidelines compared to a new risk assessment method utilizing early maternal biomarkers. The study aimed to identify women who are at high risk for developing pre-eclampsia and who may benefit from aspirin.

Criteria for High-Risk Identification

Women were categorized as high-risk based on several factors: a previous pregnancy with hypertensive disease, chronic kidney disease, autoimmune disorders, diabetes mellitus, or chronic hypertension.

Bayes’ Theorem Approach

An alternative method to detect pre-eclampsia, grounded in Bayes’ theorem, integrates various biomarkers during the 11-13 weeks of gestation for personalized risk estimation. These biomarkers include arterial pressure, uterine artery pulsatility index, serum pregnancy-associated plasma protein, and serum placental growth factor.

The Screening Program for Pre-eclampsia Study (SPREE)

Study Hypothesis and Design

The SPREE study aimed to evaluate whether first-trimester screening for pre-eclampsia using biomarkers based on Bayes’ theorem is more effective than the current NICE guidelines. Diagnosis of pre-eclampsia is confirmed through a systolic blood pressure exceeding 140 mmHg or diastolic blood pressure over 90 mmHg after 20 weeks of gestation, in conjunction with at least one additional complication such as proteinuria or renal insufficiency.

Participant Recruitment and Findings

Researchers recruited 16,747 women aged 18 and older with singleton pregnancies from April to December 2016. Women with severe illness, serious mental health issues, or major fetal abnormalities were excluded. Among the participants, 142 developed preterm pre-eclampsia. Of those screened by NICE guidelines, 400 took aspirin, compared to 349 from the NICE screened-negative group. The detection rate difference between the NICE guidelines and the Bayes’ theorem method was found to be 12.1%.

Conclusion: Early Screening Advantages

Effectiveness of Early Screening

The findings indicate that the NICE guidelines identify only about 30% of cases, with around 40% of those developing severe pre-eclampsia leading to preterm birth. In contrast, early screening using maternal biomarkers proved to be more effective, enabling better prevention strategies for women at risk of pre-eclampsia.

Study Limitations

A noted limitation of the study was the absence of formal health assessments regarding the practical implementation of combined screening techniques for pre-eclampsia.

Reference

Tan, M., Wright, D., Syngelaki, A., Akolekar, R., Cicero, S., & Janga, D. et al. (2018). Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. *Ultrasound In Obstetrics & Gynecology*.